Methylation-mediated immune evasion mechanisms in DLBCL primarily affect MHC molecules, costimulatory molecules (CD80/CD86), antigen processing machinery (TAP1/TAP2, B2M), and cytokine and interferon signaling pathways. The gene discussed is B2M; the disease is diffuse large B-cell lymphoma.